Low-dose heparin for elective percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Current guidelines recommend higher heparin doses (70-100 IU/kg) for elective percutaneous coronary intervention (PCI), potentially increasing bleeding risk.
• Low-dose heparin (40 IU/kg) has not been extensively studied for elective PCI safety and efficacy.

Purpose of the Study:

• To evaluate the safety and efficacy of a low-dose heparin regimen (40 IU/kg) during elective transfemoral percutaneous coronary intervention (PCI).

Main Methods:

• A prospective study of 300 patients undergoing elective transfemoral PCI from January 2008 to October 2012.
• Patients received a 40 IU/kg heparin bolus and dual antiplatelet therapy (clopidogrel and aspirin).
• Primary endpoint: composite of cardiac death, myocardial infarction, urgent revascularization, or major bleeding within 30 days.

Main Results:

• The primary endpoint occurred in 2.3% of patients.
• Major bleeding occurred in 0.3%; cardiac death in 0.3%; myocardial infarction in 1.3%.
• No stent thrombosis was observed.

Conclusions:

• Low-dose heparin (40 IU/kg) with dual antiplatelet therapy is safe and effective for elective transfemoral PCI, associated with low bleeding risk.
• This strategy suppressed ischemic events and may offer cost savings.
• Further randomized trials comparing low-dose heparin with bivalirudin are needed to confirm optimal anticoagulation.